VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
Industry, Sector and Symbol
Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
Phone646 650 1351
Debt
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / BookN/A
Profitability
Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A
Miscellaneous
Employees37
OptionableNot Optionable
VolitionRX (NYSEAMERICAN:VNRX) Frequently Asked Questions
What is VolitionRX's stock symbol?
VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."
How were VolitionRX's earnings last quarter?
VolitionRX Ltd (NYSEAMERICAN:VNRX) posted its earnings results on Wednesday, November, 7th. The medical research company reported ($0.14) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.14). View VolitionRX's Earnings History.
When is VolitionRX's next earnings date?
What price target have analysts set for VNRX?
4 brokerages have issued twelve-month target prices for VolitionRX's stock. Their predictions range from $5.00 to $10.00. On average, they anticipate VolitionRX's share price to reach $6.50 in the next year. This suggests a possible upside of 181.4% from the stock's current price. View Analyst Price Targets for VolitionRX.
What is the consensus analysts' recommendation for VolitionRX?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VolitionRX.
Has VolitionRX been receiving favorable news coverage?
Media stories about VNRX stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. VolitionRX earned a coverage optimism score of 1.9 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future.
Are investors shorting VolitionRX?
VolitionRX saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 327,999 shares, an increase of 80.3% from the December 14th total of 181,885 shares. Based on an average daily trading volume, of 113,840 shares, the short-interest ratio is presently 2.9 days. Approximately 1.5% of the company's shares are sold short. View VolitionRX's Current Options Chain.
Who are some of VolitionRX's key competitors?
Who are VolitionRX's key executives?
VolitionRX's management team includes the folowing people:
- Dr. Martin Charles Faulkes, Exec. Chairman (Age 74)
- Mr. Cameron Reynolds, Founder, CEO, Pres & Director (Age 47)
- Dr. Jacob Vincent Micallef Ph.D., MBA, Chief Scientific Officer (Age 62)
- Dr. Jason Bradley Terrell, Chief Medical Officer & CEO of Volition America Inc. (Age 38)
- Mr. Rodney Gerard Rootsaert LLB, Corp. Sec. (Age 47)
How do I buy shares of VolitionRX?
Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is VolitionRX's stock price today?
One share of VNRX stock can currently be purchased for approximately $2.31.
What is VolitionRX's official website?
How can I contact VolitionRX?
The medical research company can be reached via phone at 646 650 1351.
MarketBeat Community Rating for VolitionRX (NYSEAMERICAN VNRX)
MarketBeat's community ratings are surveys of what our community members think about VolitionRX and other stocks. Vote "Outperform" if you believe VNRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
